Posted inCardiagtech

Diagnosis of Alpha Thalassemia Trait: A Comprehensive Guide for Healthcare Professionals

No Comments

Alpha thalassemia trait refers to the carrier state of alpha thalassemia, a group of inherited blood disorders characterized by reduced or absent production of alpha-globin chains, a crucial component of hemoglobin. Understanding the Diagnosis Of Alpha Thalassemia Trait is vital for healthcare professionals for effective genetic counseling, family planning, and appropriate patient management. This article provides an in-depth guide to diagnosing alpha thalassemia trait, enhancing your competence in laboratory evaluation and patient care.

Understanding Alpha Thalassemia and its Traits

Hemoglobin, the protein in red blood cells responsible for oxygen transport, comprises alpha and beta globin chains. Alpha thalassemia arises from genetic defects affecting the genes that produce alpha-globin. The severity of alpha thalassemia varies widely depending on the number of affected genes. Alpha thalassemia trait occurs when individuals inherit one or two affected alpha-globin genes.

There are two main types of alpha thalassemia trait:

  • Alpha Thalassemia Minor (α-thalassemia 2 trait): Typically results from the deletion of one alpha-globin gene (-α/αα). Individuals are often asymptomatic carriers.
  • Alpha Thalassemia Minor (α-thalassemia 1 trait): Results from the deletion of two alpha-globin genes (α-/α- or –/αα). Individuals may have mild microcytic anemia.

Early and accurate diagnosis of alpha thalassemia trait is crucial, not only for identifying carriers but also for differentiating it from other conditions like iron deficiency anemia and guiding further management.

Diagnostic Approaches for Alpha Thalassemia Trait

Diagnosing alpha thalassemia trait involves a combination of laboratory tests and clinical evaluation. Here’s a detailed look at the key diagnostic tests:

1. Complete Blood Count (CBC)

A CBC is often the first-line investigation in evaluating for thalassemia. In alpha thalassemia trait, the CBC may reveal:

  • Mild Microcytosis: Red blood cells may be smaller than normal (low Mean Corpuscular Volume or MCV).
  • Mild Hypochromia: Red blood cells may have less hemoglobin than normal (low Mean Corpuscular Hemoglobin or MCH).
  • Normal or Elevated Red Blood Cell (RBC) Count: This is a key differentiator from iron deficiency anemia, where RBC count is typically low. Hemoglobin levels might be slightly reduced or within the normal range in alpha thalassemia trait.

While CBC parameters suggest thalassemia, they are not definitive for diagnosing alpha thalassemia trait and differentiating it from other microcytic anemias.

2. Iron Studies

Iron deficiency anemia (IDA) is a common cause of microcytic anemia and needs to be ruled out when investigating for thalassemia. Iron studies are essential to differentiate between these conditions.

  • Serum Ferritin: Ferritin levels are typically normal or slightly increased in alpha thalassemia trait, unlike in IDA, where ferritin is low.
  • Transferrin Saturation: Usually normal in thalassemia trait, while it’s decreased in IDA.
  • Serum Iron and Total Iron Binding Capacity (TIBC): These may be normal in thalassemia trait, whereas in IDA, serum iron is low and TIBC is high.

Normal or elevated iron stores in the presence of microcytosis suggest a diagnosis other than IDA, making thalassemia trait more likely.

3. Peripheral Blood Smear

Examination of the peripheral blood smear can provide valuable clues. In alpha thalassemia trait, the smear may show:

  • Microcytic and Hypochromic Red Blood Cells: Consistent with CBC findings.
  • Target Cells: Red blood cells with a bullseye appearance, which are not specific but can be seen in thalassemia.
  • Normal Red Cell Morphology: In some cases, especially in alpha-thalassemia 2 trait, the peripheral smear may appear relatively normal.

The peripheral smear findings are supportive but not diagnostic of alpha thalassemia trait.

4. Hemoglobin Analysis: HPLC and Electrophoresis

Hemoglobin analysis is crucial for confirming the diagnosis and differentiating alpha thalassemia trait from other hemoglobinopathies. High-Performance Liquid Chromatography (HPLC) and hemoglobin electrophoresis are commonly used techniques.

  • Hemoglobin Electrophoresis or HPLC: In alpha thalassemia trait, these tests are typically normal in adults because the reduction in alpha-globin is usually compensated by increased beta-globin production, resulting in normal HbA, HbA2, and HbF levels. However, in newborns, a small amount of Hemoglobin Bart’s (Hb Bart’s) (γ4) may be detected (1-3% in α+ trait and 3-8% in α° trait), which disappears within a few months of life. The absence of abnormal hemoglobin variants like HbS, HbC, or HbE helps rule out other hemoglobinopathies.

Alt Text: Hemoglobin electrophoresis patterns illustrating various hemoglobin disorders, including normal, sickle cell trait, beta thalassemia trait, and HbH disease, showing the migration of HbA, HbA2, HbF, HbS, HbC, and HbH.

5. Molecular Genetic Testing

Molecular testing is the gold standard for definitive diagnosis and characterization of alpha thalassemia, especially for alpha thalassemia trait. It is particularly useful in:

  • Confirming the diagnosis: Identifying specific alpha-globin gene deletions or mutations.
  • Carrier screening: Identifying silent carriers who may have normal routine blood tests.
  • Prenatal diagnosis: Assessing the risk of having a child with severe alpha thalassemia.
  • Genetic counseling: Providing accurate recurrence risks to families.

Common molecular techniques include:

  • Gap-PCR (Polymerase Chain Reaction): Detects common alpha-globin gene deletions.
  • Multiplex Ligation-dependent Probe Amplification (MLPA): Identifies deletions and duplications in the alpha-globin gene cluster.
  • DNA Sequencing: Identifies point mutations and less common deletions.
  • Real-time PCR: Offers rapid and quantitative analysis of gene deletions.

Molecular testing can distinguish between α-thalassemia 1 trait (deletion of two genes) and α-thalassemia 2 trait (deletion of one gene), providing precise genetic information for counseling.

Diagnostic Algorithm for Alpha Thalassemia Trait

A stepwise approach is recommended for diagnosing alpha thalassemia trait:

  1. Initial Screening: CBC is usually the first test performed if microcytosis is detected or thalassemia trait is suspected based on ethnicity or family history.
  2. Rule out Iron Deficiency: Perform iron studies (serum ferritin, transferrin saturation) to exclude IDA as the cause of microcytosis.
  3. Peripheral Blood Smear: Examine the blood smear for red cell morphology, although findings may be subtle in alpha thalassemia trait.
  4. Hemoglobin Analysis (HPLC or Electrophoresis): While typically normal in adult alpha thalassemia trait, it helps rule out other hemoglobinopathies and may detect Hb Bart’s in newborns.
  5. Molecular Genetic Testing: If thalassemia trait is suspected based on CBC and iron studies, or for definitive diagnosis and genetic counseling, molecular testing is recommended to confirm the diagnosis and identify the specific genetic defect.

Alt Text: Flow chart illustrating the laboratory differentiation between thalassemia and iron-deficiency anemia, starting with CBC and MCV, proceeding to ferritin levels, and differentiating based on RBC count and hemoglobin analysis.

Clinical Significance of Diagnosing Alpha Thalassemia Trait

Accurate diagnosis of alpha thalassemia trait has significant clinical implications:

  • Genetic Counseling: Identifying carriers is crucial for genetic counseling, especially for couples planning a family. If both partners are carriers of alpha thalassemia, there is a risk of having children with more severe forms of alpha thalassemia, such as HbH disease or Hb Bart’s hydrops fetalis.
  • Differentiation from Iron Deficiency Anemia: Avoids unnecessary iron supplementation in individuals with thalassemia trait who are not iron deficient. Misdiagnosis as IDA can lead to inappropriate treatment and delayed diagnosis.
  • Prenatal Diagnosis and Family Planning: Allows for prenatal testing in pregnancies at risk and informed family planning decisions.
  • Newborn Screening: In regions with a high prevalence of thalassemia, newborn screening programs may include testing for alpha thalassemia to identify affected infants and carriers early.

Conclusion

Diagnosing alpha thalassemia trait involves a systematic approach utilizing CBC, iron studies, hemoglobin analysis, and, most importantly, molecular genetic testing. While CBC and peripheral smears may provide initial clues, they are not definitive. Hemoglobin analysis is often normal in adult carriers, making molecular testing the cornerstone of accurate diagnosis.

For healthcare professionals, understanding the diagnostic algorithm and the clinical significance of alpha thalassemia trait is essential for providing comprehensive patient care, genetic counseling, and informed family planning guidance. Early and accurate diagnosis improves patient outcomes and supports families in making informed decisions regarding their reproductive health.

References

  1. Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2018 May;70:54-65.
  2. Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013 May 01;3(5):a011700.
  3. Bernini LF, Harteveld CL. Alpha-thalassaemia. Baillieres Clin Haematol. 1998 Mar;11(1):53-90.
  4. Harewood J, Azevedo AM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 4, 2023. Alpha Thalassemia.
  5. Weatherall DJ. The Evolving Spectrum of the Epidemiology of Thalassemia. Hematol Oncol Clin North Am. 2018 Apr;32(2):165-175.
  6. Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in Laboratory Diagnosis of Thalassemia. Front Mol Biosci. 2020;7:74.
  7. Rund D. Thalassemia 2016: Modern medicine battles an ancient disease. Am J Hematol. 2016 Jan;91(1):15-21.
  8. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013 Jun;98(6):833-44.
  9. Piel FB, Weatherall DJ. The α-thalassemias. N Engl J Med. 2014 Nov 13;371(20):1908-16.
  10. Poyart C, Wajcman H. Hemolytic anemias due to hemoglobinopathies. Mol Aspects Med. 1996 Apr;17(2):129-42.
  11. He S, Li J, Huang P, Zhang S, Lin L, Zuo Y, Tian X, Zheng C, Qiu X, Chen B. Characterization of Hb Bart’s Hydrops Fetalis Caused by – -SEA and a Large Novel α0-Thalassemia Deletion. Hemoglobin. 2018 Jan;42(1):61-64.
  12. Pang W, Long J, Weng X, Fan Q, Sun L, Pan Z, Fan Z. Identification of Three Types of α-Thalassemia Deletion, -α21.9, -α2.4, and – -THAI, and Their Frequencies, in One Family in the Population of Southern Guangxi Zhuang Autonomous Region, People’s Republic of China. Hemoglobin. 2018 Jan;42(1):37-42.
  13. Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a011692.
  14. Kalfa TA. Diagnosis and clinical management of red cell membrane disorders. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):331-340.
  15. Bhat VS, Dewan KK, Krishnaswamy PR. The Diagnosis of α-Thalassaemia: A Case of Hemoglobin H -α Deletion. Indian J Clin Biochem. 2010 Oct;25(4):435-40.
  16. Viprakasit V, Limwongse C, Sukpanichnant S, Ruangvutilert P, Kanjanakorn C, Glomglao W, Sirikong M, Utto W, Tanphaichitr VS. Problems in determining thalassemia carrier status in a program for prevention and control of severe thalassemia syndromes: a lesson from Thailand. Clin Chem Lab Med. 2013 Aug;51(8):1605-14.
  17. King AJ, Higgs DR. Potential new approaches to the management of the Hb Bart’s hydrops fetalis syndrome: the most severe form of α-thalassemia. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):353-360.
  18. Giordano PC. Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: interpretation of results and pitfalls. Int J Lab Hematol. 2013 Oct;35(5):465-79.
  19. Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol. 2016 May;38 Suppl 1:32-40.
  20. Hansson K, Schuring-Blom GH, Leschot NJ. The preserving of chorionic villi before establishing long-term cell cultures for cytogenetic analysis. Prenat Diagn. 1995 Nov;15(11):1067-9.
  21. Old J, Henderson S. Molecular diagnostics for haemoglobinopathies. Expert Opin Med Diagn. 2010 May;4(3):225-40.
  22. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010 May 21;5:11.
  23. Oyaert M, Van Laer C, Claerhout H, Vermeersch P, Desmet K, Pauwels S, Kieffer D. Evaluation of the Sebia Minicap Flex Piercing capillary electrophoresis for hemoglobinopathy testing. Int J Lab Hematol. 2015 Jun;37(3):420-5.
  24. Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. Blood. 2000 Jan 01;95(1):360-2.
  25. Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ, Clegg JB. Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol. 2000 Feb;108(2):295-9.
  26. Rao S, Kar R, Gupta SK, Chopra A, Saxena R. Spectrum of haemoglobinopathies diagnosed by cation exchange-HPLC & modulating effects of nutritional deficiency anaemias from north India. Indian J Med Res. 2010 Nov;132(5):513-9.
  27. Kunwandee J, Srivorakun H, Fucharoen G, Sanchaisuriya K, Fucharoen S. ARKRAY ADAMS A1c HA-8180T Analyzer for Diagnosis of Thalassemia and Hemoglobinopathies Common in Southeast Asia. Lab Med. 2014 Summer;45(3):e112-21.
  28. Khera R, Singh T, Khuana N, Gupta N, Dubey AP. HPLC in characterization of hemoglobin profile in thalassemia syndromes and hemoglobinopathies: a clinicohematological correlation. Indian J Hematol Blood Transfus. 2015 Mar;31(1):110-5.
  29. Borbely N, Phelan L, Szydlo R, Bain B. Capillary zone electrophoresis for haemoglobinopathy diagnosis. J Clin Pathol. 2013 Jan;66(1):29-39.
  30. Khongthai K, Ruengdit C, Panyasai S, Pornprasert S. Analysis of Deletional Hb H Diseases in Samples with Hb A2-Hb H and Hb A2-Hb Bart’s on Capillary Electrophoresis. Hemoglobin. 2019 Jul-Sep;43(4-5):245-248.
  31. Suwannakhon N, Pangeson T, Seeratanachot T, Mahingsa K, Pingyod A, Bumrungpakdee W, Sanguansermsri T. Noninvasive prenatal screening test for compound heterozygous beta thalassemia using an amplification refractory mutation system real-time polymerase chain reaction technique. Hematol Rep. 2019 Sep 18;11(3):8124.
  32. Qin J, He J, Li Y, Liu N, Tao F, Zhang P, Guo W, Qin Q, Zhou W. One-step genotyping of α-thalassaemia by multiplex symmetric PCR melting curve. J Clin Pathol. 2023 Sep;76(9):632-636.
  33. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O’Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG., American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013 Jul;15(7):565-74.
  34. Zhou YQ, Xiao GF, Li LY, Li WD, Liu ZY, Zhu LF, Mo QH, Qu XJ, Xu XM. Evaluation of clinical application of gap-PCR as a routine method for alpha-thalassemia carrier detection. Di Yi Jun Yi Da Xue Xue Bao. 2002 May;22(5):434-6.
  35. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002 Jun 15;30(12):e57.
  36. Slatko BE, Gardner AF, Ausubel FM. Overview of Next-Generation Sequencing Technologies. Curr Protoc Mol Biol. 2018 Apr;122(1):e59.
  37. Emms A, Castleman J, Allen S, Williams D, Kinning E, Kilby M. Next Generation Sequencing after Invasive Prenatal Testing in Fetuses with Congenital Malformations: Prenatal or Neonatal Investigation. Genes (Basel). 2022 Aug 24;13(9)
  38. Kingchaiyaphum B, Sanchaisuriya K, Fucharoen G, Chaibunruang A, Hess SY, Hinnouho GM, Barffour MA, Wessells KR, Kounnavong S, Fucharoen S. Hemoglobins F, A2 , and E levels in Laotian children aged 6-23 months with Hb E disorders: Effect of age, sex, and thalassemia types. Int J Lab Hematol. 2020 Jun;42(3):277-283.
  39. Todd D, Lai MC, Beaven GH, Huehns ER. The abnormal haemoglobins in homozygous alpha-thalassaemia. Br J Haematol. 1970 Jul;19(1):27-31.
  40. Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis. 2010 May 28;5:13.
  41. Curran M, Mikhael M, Sun WD, Lim J, Leung A, Morchi G, Chmait RH. Perinatal Management of Bart’s Hemoglobinopathy: Paradoxical Effects of Intrauterine, Transplacental, and Partial Exchange Transfusions. AJP Rep. 2020 Jan;10(1):e11-e14.
  42. Songdej D, Babbs C, Higgs DR., BHFS International Consortium. An international registry of survivors with Hb Bart’s hydrops fetalis syndrome. Blood. 2017 Mar 09;129(10):1251-1259.
  43. Ghosh K, Colah R, Manglani M, Choudhry VP, Verma I, Madan N, Saxena R, Jain D, Marwaha N, Das R, Mohanty D, Choudhary R, Agarwal S, Ghosh M, Ross C. Guidelines for screening, diagnosis and management of hemoglobinopathies. Indian J Hum Genet. 2014 Apr;20(2):101-19.
  44. Torcharus K, Sriphaisal T, Krutvecho T, Ketupanya A, Vuthiwong C, Suwanasophon C, Noonai A. Prenatal diagnosis of Hb Bart’s hydrops fetalis by PCR technique: Pramongkutklao experience. Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:287-90.
  45. Dame C, Albers N, Hasan C, Bode U, Eigel A, Hansmann M, Brenner R, Bartmann P. Homozygous alpha-thalassaemia and hypospadias–common aetiology or incidental association? Long-term survival of Hb Bart’s hydrops syndrome leads to new aspects for counselling of alpha-thalassaemic traits. Eur J Pediatr. 1999 Mar;158(3):217-20.
  46. Fenta DA, Ali MM. Factors Affecting Quality of Laboratory Result During Ordering, Handling, and Testing of the Patient’s Specimen at Hawassa University College of Medicine and Health Science Comprehensive Specialized Hospital. J Multidiscip Healthc. 2020;13:809-821.
  47. Kinns H, Pitkin S, Housley D, Freedman DB. Internal quality control: best practice. J Clin Pathol. 2013 Dec;66(12):1027-32.
  48. Laudus N, Nijs L, Nauwelaers I, Dequeker EMC. The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories. Cancers (Basel). 2022 Jul 28;14(15)
  49. Skitek M, Martinello F, Jerin A. How to Really Understand and Improve the System of Internal Quality Control and External Quality Assessment in the Accreditation Process of the Medical Laboratory? EJIFCC. 2022 Apr;33(1):23-27.
  50. Lock RJ. My approach to internal quality control in a clinical immunology laboratory. J Clin Pathol. 2006 Jul;59(7):681-4.
  51. Petersen PH, Ricós C, Stöckl D, Libeer JC, Baadenhuijsen H, Fraser C, Thienpont L. Proposed guidelines for the internal quality control of analytical results in the medical laboratory. Eur J Clin Chem Clin Biochem. 1996 Dec;34(12):983-99.
  52. Abu-Siniyeh A, Al-Shehri SS. Safety in Medical Laboratories: Perception and Practice of University Students and Laboratory Workers. Appl Biosaf. 2021 Sep;26(Suppl 1):S34-S42.
  53. Bayot ML, Limaiem F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 30, 2023. Biosafety Guidelines.
  54. Cornish NE, Anderson NL, Arambula DG, Arduino MJ, Bryan A, Burton NC, Chen B, Dickson BA, Giri JG, Griffith NK, Pentella MA, Salerno RM, Sandhu P, Snyder JW, Tormey CA, Wagar EA, Weirich EG, Campbell S. Clinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future. Clin Microbiol Rev. 2021 Jun 16;34(3):e0012618.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *